Document is current

Article History

Received: 3 February 2025

Accepted: 19 March 2025

First Online: 26 March 2025

Declarations

:

: T.F. has received speaker fees from AbbVie GK, Astellas Pharma Inc, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co., Taisho Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K. K.Murata received research grants and/or speaker fees from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co., Ltd., Daiichi Sankyo Co., Ltd., and Astellas Pharma Inc. A.O. received research grants and speaker fees from Pfizer Inc., Bristol Myers Squibb, Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. K.Murakami received speaking and/or consulting fees from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Bristol-Myers Squibb, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., and Asahi Kasei Pharma Corp. M.T. has received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Pfizer Inc., Taisho Pharmaceutical Co., Ltd., Tanabe Mitsubishi Pharma Corp., Teijin Pharma, Ltd., UCB Japan Co., Ltd. K.N. has received speaker fees from Pfizer Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., AbbVie Inc., Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd, and Viatris Inc. Y.E. received research grants and/or speaker fees from Asahi Kasei, Eisai, Eli Lilly, Mitsubishi Tanabe, Ono Pharmaceuticals, and Taisho. Y.E. is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. Y.O. has received lecture fees from Chugai, Pfizer and Ono. H. A. has received speaker fees from Asahi Kasei Pharma, Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd, Taisho Pharmaceutical Co., and Mitsubishi Tanabe Pharma. T.O. has received research grants from Abbvie, Asahi Kasei, Chugai, Eisai, and Tanabe Mitsubishi, and speaker fees from Abbvie, Asahi Kasei, Chugai, Eisai, Eli Lilly, Janssen, Novartis Pharma and Tanabe Mitsubishi. K. Y.U. has received speaker fees from AbbVie, Asahi Kasei Pharma, Astellas, Bristol Meyers Squibb, Chugai, Eisai, Eli Lilly, Gilead Sciences, and Taiho Pharmaceutical. R.H. received speaker fees from AbbVie, Eli Lilly, Eisai, and Asahi Kasei. M.H. received research grants and/or speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, EA Pharma, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, Taisho Toyama, and Tanabe Mitsubishi. A.M. received honorarium and research grants from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., Asahi Kasei Pharma Corp., and Gilead Sciences Japan. S.M. received research grants and/or speaker fees from Takeda, Eisai, Asahi-Kasei, Astellas, Pfizer, Taisho, Mitsubishi-Tanabe, and Chugai. Other authors have no conflicts of interest to disclose concerning this manuscript.

: The institutional review board at all hospitals participating in the KURAMA and the ANSWER cohorts approved this study. Written informed consent was obtained from all participants.

: Not applicable.